GMED vs QGEN
Globus Medical vs Qiagen N.V. — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
| Metric | GMED | QGEN |
|---|
| AI Score |
71
|
64
|
| Price |
$85.12
|
$42.66
|
| P/E Ratio |
21.45×
|
21.87×
|
| ROE |
11.8%
|
11.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
61.7%
|
| Debt / Equity |
0.02×
|
0.49×
|
| Dividend Yield |
0.0%
|
6.2%
|
| RSI (14) |
75.9
|
57.5
|
| Beta |
0.954
|
0.62
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus QGEN.
GMED leads by 7 points.
GMED scores 71/100 (Buy) versus QGEN at 64/100 (Buy).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
QGEN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- EPS growing 341.4% YoY — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro